Scholar Rock wins FDA approval for ISEMBYLD, the first muscle-targeted treatment for spinal muscular atrophy

By Sep 12, 2026

Regulatory Approvals — Scholar Rock wins FDA approval for ISEMBYLD, the first muscle-targeted treatment for spinal muscular atrophy Dealroom

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 12, 2026.

By

Regulatory Approvals

FDA Approves Apitegromab for Spinal Muscular Atrophy

Sep 12, 2026

Regulatory Approvals

Scholar Rock wins FDA approval for first drug to target SMA muscle loss

Sep 12, 2026

Regulatory Approvals

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

Sep 12, 2026

Scholar Rock wins FDA approval for ISEMBYLD, the first muscle-targeted treatment for spinal muscular atrophy

By

Financial News For All

Vorys Benefits Brief: Recent Court Decisions Affecting Withdrawal Liability

Joint Readout of Principals’ Meeting of U.S. and UK Authorities Regarding Central Counterparty Resolution

EPA begins cleanup at Rumsey Mill in Montana

Commodities Price Update: Crude Oil $100.05, Brent $104.61, Copper $6.55, Coal $104.75 — Sep 12, 2026 8:00 AM EDT

Scholar Rock wins FDA approval for ISEMBYLD, the first muscle-targeted treatment for spinal muscular atrophy

By

Related Post

FDA Approves Apitegromab for Spinal Muscular Atrophy

Scholar Rock wins FDA approval for first drug to target SMA muscle loss

FDA approves first-of-its-kind drug rusfertide for polycythemia vera

Financial News For All

Vorys Benefits Brief: Recent Court Decisions Affecting Withdrawal Liability

Joint Readout of Principals’ Meeting of U.S. and UK Authorities Regarding Central Counterparty Resolution

EPA begins cleanup at Rumsey Mill in Montana

Commodities Price Update: Crude Oil $100.05, Brent $104.61, Copper $6.55, Coal $104.75 — Sep 12, 2026 8:00 AM EDT